Omega-3 fatty acids for intermittent claudication

Abstract

Omega-3 fatty acids appear to have limited haematological benefits in people with intermittent claudication but there is no evidence of consistent improved clinical outcomes which are the primary outcomes of this review (quality of life, PFWD, MWD, ABPI, angiographic findings). Supplementation may also cause adverse effects such as increased total and LDL cholesterol levels. Further research is needed in this area, to evaluate short- and long-term effects on more clinically relevant outcomes.

The role of nutrition and body composition in peripheral arterial disease

“…61 A meta-analysis of data from six trials of omega-3 supplementation, showed that the supplements had no discernible net impact on PAD outcomes, although the researchers did note a moderate increase in blood viscosity among individuals taking EFA capsules. 68 These results are similar to those of previous systematic reviews and meta-analyses of the effect of polyunsaturated fat supplementation on the risks of coronary and cerebrovascular events and mortality. 69–72 A small clinical trial of 32 patients also showed that omega-3 supplements did not improve the symptoms of PAD.…”

The role of nutrition and body composition in peripheral arterial disease

“…61 A meta-analysis of data from six trials of omega-3 supplementation, showed that the supplements had no discernible net impact on PAD outcomes, although the researchers did note a moderate increase in blood viscosity among individuals taking EFA capsules. 68 These results are similar to those of previous systematic reviews and meta-analyses of the effect of polyunsaturated fat supplementation on the risks of coronary and cerebrovascular events and mortality. 69–72 A small clinical trial of 32 patients also showed that omega-3 supplements did not improve the symptoms of PAD.…”

Polyunsaturated fatty acids and peripheral artery disease

“…100 The study identified six randomized controlled trials assessing the effects of n-3 FAs in patients with IC, representing 313 participants. All studies assessed n-3 dietary supplementation versus placebo, with the treatment duration lasting between 4 weeks and 2 years.…”

Supplementation of N‐3 LCPUFA to the Diet of Children Older Than 2 Years: A Commentary by the ESPGHAN Committee on Nutrition

“…Numerous clinical studies have addressed the effect of n-3 LCPUFA supplementation in restoring health and maintaining well-being. The results of these studies have been summarised in reviews including several recent Cochrane Database Systematic Reviews addressing the potential role of n-3 LCPUFA adjuvant therapy in bipolar disorder (10), cancer cachexia (11), Crohn disease (12), cystic fibrosis (CF) (13), diabetes mellitus (14), end-stage renal disease after kidney transplantation (15), intermittent claudication (16), multiple sclerosis (17), and ulcerative colitis (18).…”

The role of nutrition and body composition in peripheral arterial disease

“…61 A meta-analysis of data from six trials of omega-3 supplementation, showed that the supplements had no discernible net impact on PAD outcomes, although the researchers did note a moderate increase in blood viscosity among individuals taking EFA capsules. 68 These results are similar to those of previous systematic reviews and meta-analyses of the effect of polyunsaturated fat supplementation on the risks of coronary and cerebrovascular events and mortality. 69–72 A small clinical trial of 32 patients also showed that omega-3 supplements did not improve the symptoms of PAD.…”

Polyunsaturated fatty acids and peripheral artery disease

“…100 The study identified six randomized controlled trials assessing the effects of n-3 FAs in patients with IC, representing 313 participants. All studies assessed n-3 dietary supplementation versus placebo, with the treatment duration lasting between 4 weeks and 2 years.…”

Supplementation of N‐3 LCPUFA to the Diet of Children Older Than 2 Years: A Commentary by the ESPGHAN Committee on Nutrition

“…Numerous clinical studies have addressed the effect of n-3 LCPUFA supplementation in restoring health and maintaining well-being. The results of these studies have been summarised in reviews including several recent Cochrane Database Systematic Reviews addressing the potential role of n-3 LCPUFA adjuvant therapy in bipolar disorder (10), cancer cachexia (11), Crohn disease (12), cystic fibrosis (CF) (13), diabetes mellitus (14), end-stage renal disease after kidney transplantation (15), intermittent claudication (16), multiple sclerosis (17), and ulcerative colitis (18).…”

The role of nutrition and body composition in peripheral arterial disease

“…61 A meta-analysis of data from six trials of omega-3 supplementation, showed that the supplements had no discernible net impact on PAD outcomes, although the researchers did note a moderate increase in blood viscosity among individuals taking EFA capsules. 68 These results are similar to those of previous systematic reviews and meta-analyses of the effect of polyunsaturated fat supplementation on the risks of coronary and cerebrovascular events and mortality. 69–72 A small clinical trial of 32 patients also showed that omega-3 supplements did not improve the symptoms of PAD.…”

Polyunsaturated fatty acids and peripheral artery disease

“…100 The study identified six randomized controlled trials assessing the effects of n-3 FAs in patients with IC, representing 313 participants. All studies assessed n-3 dietary supplementation versus placebo, with the treatment duration lasting between 4 weeks and 2 years.…”

Supplementation of N‐3 LCPUFA to the Diet of Children Older Than 2 Years: A Commentary by the ESPGHAN Committee on Nutrition

“…Numerous clinical studies have addressed the effect of n-3 LCPUFA supplementation in restoring health and maintaining well-being. The results of these studies have been summarised in reviews including several recent Cochrane Database Systematic Reviews addressing the potential role of n-3 LCPUFA adjuvant therapy in bipolar disorder (10), cancer cachexia (11), Crohn disease (12), cystic fibrosis (CF) (13), diabetes mellitus (14), end-stage renal disease after kidney transplantation (15), intermittent claudication (16), multiple sclerosis (17), and ulcerative colitis (18).…”